Payment overview · 2025
General Payments
$1,563.48
94 reported records · 17 companies
Healthcare provider profile · identity verified
Craig Mcmullen, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MINEOLA, TX · NPI 1487614616
Verified facts
What the public records show
CMS Open Payments records show Craig Mcmullen, M.D. received $1,563.48 in general payments during 2025 across 94 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $318.30 | 20.4% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $288.56 | 18.5% | 24 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $233.37 | 14.9% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $173.88 | 11.1% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $162.68 | 10.4% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.91 | 4.1% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $58.62 | 3.8% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $48.44 | 3.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $42.81 | 2.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.03 | 2.4% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $34.57 | 2.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.31 | 1.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.69 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.69 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.46 | 0.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.87 | 0.9% | 1 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $10.29 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,563.48 | 94 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $288.56 | 24 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $233.37 | 13 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $173.88 | 12 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $162.68 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $132.47 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $106.79 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $79.04 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $63.91 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $58.62 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $48.44 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $42.81 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $37.03 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $34.57 | 2 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $10.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 65 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 173 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 297 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 132 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
84 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
132 | 31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
173 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
297 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
175 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 847 | 239 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 826 | 238 |
| Amlodipine Besylate | Amlodipine Besylate | 605 | 189 |
| Atorvastatin Calcium | Atorvastatin Calcium | 593 | 197 |
| Lisinopril | Lisinopril | 479 | 144 |
| Gabapentin | Gabapentin | 447 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 369 | 120 |
| Tamsulosin Hcl | Tamsulosin Hcl | 321 | 102 |
| Trazodone Hcl | Trazodone Hcl | 306 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 91 |
| Ozempic | Semaglutide | 297 | 47 |
| Spironolactone | Spironolactone | 283 | 92 |
| Omeprazole | Omeprazole | 269 | 84 |
| Allopurinol | Allopurinol | 259 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 255 | 66 |
| Furosemide | Furosemide | 248 | 84 |
| Losartan Potassium | Losartan Potassium | 236 | 83 |
| Metformin Hcl | Metformin Hcl | 234 | 70 |
| Potassium Chloride | Potassium Chloride | 204 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 197 | 58 |
| Simvastatin | Simvastatin | 193 | 57 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 186 | 35 |
| Meloxicam | Meloxicam | 178 | 62 |
| Pregabalin | Pregabalin | 178 | 39 |
| Eliquis | Apixaban | 175 | 42 |
| Mounjaro | Tirzepatide | 173 | 29 |
| Carvedilol | Carvedilol | 170 | 58 |
| Telmisartan | Telmisartan | 167 | 65 |
| Tramadol Hcl | Tramadol Hcl | 165 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 164 | 40 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 159 | 44 |
| Montelukast Sodium | Montelukast Sodium | 159 | 47 |
| Clonazepam | Clonazepam | 149 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 147 | 41 |
| Ropinirole Hcl | Ropinirole Hcl | 142 | 32 |
| Celecoxib | Celecoxib | 135 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 132 | 31 |
| Sertraline Hcl | Sertraline Hcl | 129 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 35 |
| Famotidine | Famotidine | 123 | 41 |
| Alprazolam | Alprazolam | 120 | 32 |
| Prednisone | Prednisone | 119 | 79 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 113 | 23 |
| Temazepam | Temazepam | 113 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 111 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 28 |
| Metformin Hcl Er | Metformin Hcl | 107 | 38 |
| Trulicity | Dulaglutide | 100 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 98 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 34 |
| Linzess | Linaclotide | 84 | 22 |
| Estradiol | Estradiol | 83 | 25 |
| Ezetimibe | Ezetimibe | 82 | 29 |
| Fluconazole | Fluconazole | 80 | 62 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 26 |
| Glimepiride | Glimepiride | 76 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 75 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 74 | 18 |
| Diazepam | Diazepam | 72 | 17 |
| Alendronate Sodium | Alendronate Sodium | 69 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 18 |
| Bupropion Xl | Bupropion Hcl | 68 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 67 | 19 |
| Ondansetron Odt | Ondansetron | 67 | 32 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 65 | 21 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 65 | 51 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 20 |
| Jardiance | Empagliflozin | 65 | 17 |
| Torsemide | Torsemide | 62 | 21 |
| Levofloxacin | Levofloxacin | 61 | 50 |
| Ibuprofen | Ibuprofen | 60 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 60 | 19 |
| Lorazepam | Lorazepam | 57 | 12 |
| Memantine Hcl | Memantine Hcl | 57 | 12 |
| Buspirone Hcl | Buspirone Hcl | 56 | 13 |
| Synthroid | Levothyroxine Sodium | 55 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 16 |
| Mirtazapine | Mirtazapine | 54 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | 13 |
| Levetiracetam | Levetiracetam | 51 | 12 |
| Aripiprazole | Aripiprazole | 50 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Fenofibrate | Fenofibrate | 46 | 12 |
| Atenolol | Atenolol | 44 | 13 |
| Cefdinir | Cefdinir | 44 | 41 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 17 |
| Valsartan | Valsartan | 44 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 11 |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | 11 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Finasteride | Finasteride | 34 | 14 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 32 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 19 |
| Cephalexin | Cephalexin | 31 | 22 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Methocarbamol | Methocarbamol | 30 | 15 |
| Valacyclovir | Valacyclovir Hcl | 30 | 14 |
| Chlorthalidone | Chlorthalidone | 29 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | 11 |
| Mupirocin | Mupirocin | 29 | 19 |
| Prolia | Denosumab | 29 | 19 |
| Ramipril | Ramipril | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 25 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 26 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Colestipol Hcl | Colestipol Hcl | 23 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Belsomra | Suvorexant | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 13 |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Caplyta | Lumateperone Tosylate | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,563.48 · 94 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Azstarys, BREZTRI, CAPLYTA, Cologuard Collection Kit, Da Vinci Surgical System, Dyanavel XR, FANAPT, FARXIGA, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, NUZYRA, Ozempic, TRELEGY ELLIPTA, VRAYLAR, Wegovy, XHANCE, XIFAXAN, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error